The Retinal Degeneration Fund (RD Fund) is a 501(c)(3) not-for-profit subsidiary of the Foundation Fighting Blindness. Launched in 2018 as the venture arm of the Foundation and with $72 million under management, the RD Fund focuses on making mission-related investments in companies with projects nearing clinical testing.
The RD Fund is changing how the world treats blinding retinal diseases. Click here to download the January 2021 Outcomes & Outlook Report.
The RD Fund has an independent Board of Directors comprised of prominent investors, business executives, and clinicians to oversee the portfolio of investments, and to ensure alignment with the Foundation’s mission. They are also charged with balancing risk versus return, and to ensure diversification of indications and therapies within the category.
RD Fund’s seasoned management team is deeply aligned with the Foundation’s mission and are actively seeking and vetting viable and beneficial partnerships.